Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research report released on Wednesday morning,Benzinga reports. Chardan Capital currently has a $24.00 price objective on the stock. STOK has been the topic of a number of other research reports. Needham & Company LLC restated a “buy” rating […]
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research report released on Wednesday morning,Benzinga reports. Chardan Capital currently has a $24.00 price objective on the stock. STOK has been the topic of a number of other research reports. Needham & Company LLC restated a “buy” rating […]
